134 results on '"Landry, Nathalie"'
Search Results
2. Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates
3. Elimination of receptor binding by influenza hemagglutinin improves vaccine-induced immunity
4. Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities
5. Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19
6. Lack of effects on female fertility or pre- and postnatal development of offspring in rats after exposure to AS03-adjuvanted recombinant plant-derived virus-like particle vaccine candidate for COVID-19
7. Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19
8. Morphological characterization of a plant-made virus-like particle vaccine bearing influenza virus hemagglutinins by electron microscopy
9. Plant-made virus-like particles bearing influenza hemagglutinin (HA) recapitulate early interactions of native influenza virions with human monocytes/macrophages
10. Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro
11. Prime-pull vaccination with a plant-derived virus-like particle influenza vaccine elicits a broad immune response and protects aged mice from death and frailty after challenge
12. Analysis of Influenza Vaccines
13. A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults
14. Influenza Virus-Like Particles Produced in Nicotiana benthamiana Protect Against a Lethal Viral Challenge in Mice
15. Plant-derived virus-like particle vaccines drive cross-presentation of influenza A hemagglutinin peptides by human monocyte-derived macrophages
16. Human antibody response to N-glycans present on plant-made influenza virus-like particle (VLP) vaccines
17. Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens
18. Humoral and cell-mediated immune responses to H5N1 plant-made virus-like particle vaccine are differentially impacted by alum and GLA-SE adjuvants in a Phase 2 clinical trial
19. Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine
20. Analysis of Influenza Vaccines
21. Durability and Cross-Reactivity of Immune Responses Induced by an AS03-Adjuvanted Plant-Based Recombinant Virus-Like Particle Vaccine for COVID-19
22. Influenza Virus-Like Particles Produced in Nicotiana benthamiana Protect Against a Lethal Viral Challenge in Mice
23. Phase 2 Randomized Trial of an AS03 Adjuvanted Plant-Based Virus-Like Particle Vaccine for Covid-19 in Healthy Adults, Older Adults and Adults with Comorbidities
24. Safety, immunogenicity and protection provided by unadjuvanted and adjuvanted formulations of recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in non-human primates
25. Phase III: Randomized observer-blind trial to evaluate lot-to-lot consistency of a new plant-derived quadrivalent virus like particle influenza vaccine in adults 18–49 years of age
26. Phase 1 trial of a Candidate Recombinant Virus-Like Particle Vaccine for Covid-19 Disease Produced in Plants
27. Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18–64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials
28. Plants as an innovative and accelerated vaccine-manufacturing solution: a plant-based expression system could provide greater speed and capacity than other recombinant technologies at a comparatively low cost
29. Immunogenicity and safety of a quadrivalent plant-derived virus like particle influenza vaccine candidate—Two randomized Phase II clinical trials in 18 to 49 and ≥50 years old adults
30. Intracellular Tracking of Influenza Hemagglutinin in Human Monocyte-Derived Macrophages Measured by Image Cross Correlation Spectroscopy
31. A plant-derived VLP influenza vaccine elicits a balanced immune response even in very old mice with co-morbidities
32. Characterization of the innate stimulatory capacity of plant-derived virus-like particles bearing influenza hemagglutinin
33. The adjuvant GLA-AF enhances human intradermal vaccine responses
34. The establishment of surrogates and correlates of protection: Useful tools for the licensure of effective influenza vaccines?
35. A Single Intramuscular Dose of a Plant-Made Virus-Like Particle Vaccine Elicits a Balanced Humoral and Cellular Response and Protects Young and Aged Mice from Influenza H1N1 Virus Challenge despite a Modest/Absent Humoral Response
36. Case study: Application of mass spectrometry for evaluation of N-glycans, lipids and protein impurities in a plant-made influenza VLP vaccine
37. Generation and characterization of a trackable plant-made influenza H5 virus-like particle (VLP) containing enhanced green fluorescent protein (eGFP)
38. Biochemical composition of haemagglutinin‐based influenza virus‐like particle vaccine produced by transient expression in tobacco plants
39. Preclinical and Clinical Development of Plant-Made Virus-Like Particle Vaccine against Avian H5N1 Influenza
40. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza
41. Influenza virus-like particles produced by transient expression inNicotiana benthamianainduce a protective immune response against a lethal viral challenge in mice
42. Biochemical composition of haemagglutinin-based influenza virus-like particle vaccine produced by transient expression in tobacco plants.
43. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza.
44. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.
45. MOESM2 of Prime-pull vaccination with a plant-derived virus-like particle influenza vaccine elicits a broad immune response and protects aged mice from death and frailty after challenge
46. MOESM3 of Prime-pull vaccination with a plant-derived virus-like particle influenza vaccine elicits a broad immune response and protects aged mice from death and frailty after challenge
47. MOESM1 of Prime-pull vaccination with a plant-derived virus-like particle influenza vaccine elicits a broad immune response and protects aged mice from death and frailty after challenge
48. MOESM3 of Prime-pull vaccination with a plant-derived virus-like particle influenza vaccine elicits a broad immune response and protects aged mice from death and frailty after challenge
49. MOESM2 of Prime-pull vaccination with a plant-derived virus-like particle influenza vaccine elicits a broad immune response and protects aged mice from death and frailty after challenge
50. Le toucher : Soin et moyen de communication dans la pratique I.D.E.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.